WallStreetZenWallStreetZen

NASDAQ: CTKB
Cytek Biosciences Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CTKB past revenue growth

How has CTKB's revenue growth performed historically?
Company
12.59%
Industry
10.46%
Market
16.68%
CTKB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CTKB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CTKB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CTKB earnings and revenue history

Current Revenue
$197.7M
Current Earnings
-$17.6M
Current Profit Margin
-8.9%

CTKB Return on Equity

Current Company
-4.4%
Current Industry
9.3%
Current Market
34.1%
CTKB's Return on Equity (-4.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CTKB announces earnings.

CTKB Return on Assets

Current Company
-3.5%
Current Industry
5.5%
CTKB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CTKB Return on Capital Employed

Current Company
-3.41%
Current Industry
8.9%
CTKB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CTKB vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CTKB$197.71M-$4.77M-$17.56M+92.48%N/A
KIDS$175.07M-$7.15M-$25.12M+22.59%N/A
SIBN$150.71M-$32.13M-$40.85M+20.10%N/A
BVS$536.89M$43.28M-$41.96M+75.33%N/A
OFIX$771.65M-$46.43M-$120.49M+11.01%N/A
View Top Medical Device Stocks

Cytek Biosciences Earnings & Revenue FAQ

What were CTKB's earnings last quarter?

On Invalid Date, Cytek Biosciences (NASDAQ: CTKB) reported Q2 2024 earnings per share (EPS) of -$0.08, up 166.67% year over year. Total Cytek Biosciences earnings for the quarter were -$10.43 million. In the same quarter last year, Cytek Biosciences's earnings per share (EPS) was -$0.03.

If you're new to stock investing, here's how to buy Cytek Biosciences stock.

What was CTKB's earnings growth in the past year?

As of Q3 2024, Cytek Biosciences's earnings has grown year over year. Cytek Biosciences's earnings in the past year totalled -$17.56 million.

What was CTKB's revenue last quarter?

On Invalid Date, Cytek Biosciences (NASDAQ: CTKB) reported Q2 2024 revenue of $46.62 million up 6.19% year over year. In the same quarter last year, Cytek Biosciences's revenue was $49.69 million.

What was CTKB's revenue growth in the past year?

As of Q3 2024, Cytek Biosciences's revenue has grown 12.59% year over year. This is 2.13 percentage points higher than the US Medical Devices industry revenue growth rate of 10.46%. Cytek Biosciences's revenue in the past year totalled $197.71 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.